ak 2123 has been researched along with Hypoxia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aibe, N; Kagiya, T; Nakamura, S; Nishimura, T; Okabe, H; Yamazaki, H; Yoshida, K | 1 |
| Banerjee, S; Chakraborty, S; Das, T; Kagiya, VT; Mukherjee, A; Nair, CK; Samuel, G; Sarma, HD; Venkatesh, M | 1 |
2 other study(ies) available for ak 2123 and Hypoxia
| Article | Year |
|---|---|
Intensity-modulated radiation therapy with hypoxic sensitizer AK-2123 (sanazole) for glioblastoma multiforme using simultaneous integrated boost technique.
Topics: Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; Hypoxia; Middle Aged; Prognosis; Radiation-Sensitizing Agents; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Triazoles | 2013 |
Preparation and preliminary biological evaluation of a 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia.
Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Fibrosarcoma; Hypoxia; Lutetium; Mice; Neoplasms; Radioisotopes; Radiopharmaceuticals; Tissue Distribution; Triazoles | 2004 |